Recruit Rockstars Podcast #367: How His VC-Backed Team Made Drug Development Faster

When creating new drugs, it’s often difficult to find enough patients for clinical trials.

And that limits the number of trials you can run.

Which slows down drug development. And costs lives.

Charles Fisher is out to change all that.

He’s CEO of Unlearn.AI

Based in San Francisco, Unlearn helps biopharma companies develop drugs more efficiently by leveraging AI to reduce the number of patients required for placebo controls in clinical trials.

In fact, Unlearn.AI enables clinical trials that are twice as fast, require fewer patients, produce better evidence about efficacy, and in which fewer patients need to be given placebos.

Last week, the company announced a major venture investment from Epic Ventures, Alumni Ventures Group, and the global Pharma company Eisai

Charles & his team are creating the first commercial product providing AI-derived Intelligent Control Arms to increase the statistical power of clinical trials, and accelerate study timelines in Alzheimer’s Disease.

In this 20-minute conversation, he reveals how he’s scaling the team.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

AD/PD 2021: Unlearn will present novel, AI-driven approaches to enabling smaller, more efficient Alzheimer’s clinical trials

Press

How Digital Twin Technology is Disrupting Healthcare

Press

Next-gen digital health innovation in clinical trials

The Rock Health team reflects on the evolution of digital in clinical trials, discuss the current state, and explore the opportunity to further transform drug discovery.
The use of digital twins in the healthcare industry is revolutionizing clinical processes.
Join us at The 15th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, March 9 - 14, 2021.